RxDoctor Payments Data

Louis Arnold, APRN

Family · Marietta, GANPI 1447708557

Payments from drug & device makers

$1,425in general payments, 2019–2025

Across 35 payments — averaging $40.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$359
  • Medtronic$307
  • SRS Medical Systems, Inc.$175
  • Astellas Pharma US Inc$165
  • Ferring Pharmaceuticals Inc.$81
  • 180 Medical, Inc.$59
  • plus $278 from 11 others

What the payments were for

  • Speaking & faculty fees$1198%
  • Food & beverage$1,14180%
  • Education$16512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,425 in reported general payments places this provider in the 70th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$126,048
Medicare patients
490
Services billed
8,429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron93$63,932
MyrbetriqMirabegron99$63,591
Abiraterone Acetate13$24,897
Testosterone31$6,515
Tamsulosin Hcl276$3,957
Methenamine Hippurate40$3,894
Potassium Citrate ErPotassium Citrate18$2,886
Solifenacin Succinate15$2,506
Testosterone Cypionate45$1,982
Estradiol25$1,881
Trimethoprim17$1,305
Finasteride96$1,131
Fesoterodine Fumarate ErFesoterodine Fumarate13$762
Oxybutynin Chloride ErOxybutynin Chloride25$659
Trospium Chloride11$530

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$359$63,93293 claims
Astellas Pharma US IncMyrbetriq$165$63,59199 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,258 family providers in Georgia.

Other family in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →